Sacral neuromodulation for Organophosphate-induced delayed neuropathy neurogenic lower urinary tract dysfunction: a case report.
Neurogenic bladder
Organophosphate-induced delayed neuropathy (OPIDN)
Organophosphorus compounds
Peripheral nerve axons
Sacral neuromodulation
Journal
BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571
Informations de publication
Date de publication:
04 Oct 2024
04 Oct 2024
Historique:
received:
18
05
2024
accepted:
23
09
2024
medline:
5
10
2024
pubmed:
5
10
2024
entrez:
4
10
2024
Statut:
epublish
Résumé
Organophosphate-Induced Delayed Neuropathy (OPIDN) is a rare neurological disorder triggered by exposure to organophosphorus compounds. These compounds exert their neurotoxic effects by impacting the nervous system, leading to systemic manifestations. Urinary system symptoms are infrequently observed in clinical settings. Currently, effective therapeutic interventions for OPIDN-related urinary symptoms are lacking. Sacral nerve modulation therapy, an FDA-approved approach for managing lower urinary tract symptoms, presents as a promising option. Herein, we present a case of OPIDN-induced lower urinary tract obstruction successfully treated with sacral nerve modulation therapy, resulting in substantial symptom relief. A 27-year-old male patient presented with severe bilateral hydronephrosis, attributed to low bladder compliance and accompanied by a fever persisting for 6 days. The patient's medical history revealed accidental ingestion of organophosphate pesticide (Dimethoate) with no concomitant underlying diseases. In consideration of the potential for OPIDN, surgical intervention in the form of sacral neuromodulation (phase I) was undertaken. Subsequent evaluation one month post-surgery revealed notable improvements in both bladder compliance and bilateral hydronephrosis, necessitating sacral neuromodulation (phase II). Presently, following a 5-month follow-up period, the patient remains asymptomatic and in favorable health. This patient achieved long-term relief using sacral neuromodulation.
Sections du résumé
BACKGROUND
BACKGROUND
Organophosphate-Induced Delayed Neuropathy (OPIDN) is a rare neurological disorder triggered by exposure to organophosphorus compounds. These compounds exert their neurotoxic effects by impacting the nervous system, leading to systemic manifestations. Urinary system symptoms are infrequently observed in clinical settings. Currently, effective therapeutic interventions for OPIDN-related urinary symptoms are lacking. Sacral nerve modulation therapy, an FDA-approved approach for managing lower urinary tract symptoms, presents as a promising option. Herein, we present a case of OPIDN-induced lower urinary tract obstruction successfully treated with sacral nerve modulation therapy, resulting in substantial symptom relief.
CASE REPORT
METHODS
A 27-year-old male patient presented with severe bilateral hydronephrosis, attributed to low bladder compliance and accompanied by a fever persisting for 6 days. The patient's medical history revealed accidental ingestion of organophosphate pesticide (Dimethoate) with no concomitant underlying diseases. In consideration of the potential for OPIDN, surgical intervention in the form of sacral neuromodulation (phase I) was undertaken. Subsequent evaluation one month post-surgery revealed notable improvements in both bladder compliance and bilateral hydronephrosis, necessitating sacral neuromodulation (phase II). Presently, following a 5-month follow-up period, the patient remains asymptomatic and in favorable health.
CONCLUSION
CONCLUSIONS
This patient achieved long-term relief using sacral neuromodulation.
Identifiants
pubmed: 39367402
doi: 10.1186/s12894-024-01600-x
pii: 10.1186/s12894-024-01600-x
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
213Informations de copyright
© 2024. The Author(s).
Références
Richardson RJ, Fink JK, Glynn P, Hufnagel RB, Makhaeva GF, Wijeyesakere SJ. Neuropathy target esterase (NTE/PNPLA6) and organophosphorus compound-induced delayed neurotoxicity (OPIDN). Adv Neurotoxicol. 2020;4:1–78.
doi: 10.1016/bs.ant.2020.01.001
pubmed: 32518884
pmcid: 7271139
Ding Q, Fang S, Chen X, Wang Y, Li J, Tian F, et al. TRPA1 channel mediates organophosphate-induced delayed neuropathy. Cell Discovery. 2017;3:17024.
doi: 10.1038/celldisc.2017.24
pubmed: 28894590
pmcid: 5537602
Mendes PA, Pereira TC, Pina R, Santos R. Chlorpyrifos-induced delayed neurotoxicity with a rare presentation of flaccid quadriplegia: a diagnostic challenge. Eur J Case Rep Intern Med. 2018;5:751.
Pannu AK, Bhalla A, Vishnu RI, Dhibar DP, Sharma N, Vijayvergiya R. Organophosphate induced delayed neuropathy after an acute cholinergic crisis in self-poisoning. Clin Toxicol (Phila Pa). 2021;59:488–92.
doi: 10.1080/15563650.2020.1832233
Nayak P, Mallick AK, Mishra S, Panigrahy D. Organophosphorus-induced toxic myeloneuropathy: series of three adolescent patients with short review. J Pediatr Neurosci. 2019;14:42–5.
doi: 10.4103/JPN.JPN_45_18
pubmed: 31316643
pmcid: 6601111
Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol. 2015;14:720–32.
doi: 10.1016/S1474-4422(15)00070-8
pubmed: 26067125
Tudor KI, Sakakibara R, Panicker JN. Neurogenic lower urinary tract dysfunction: evaluation and management. J Neurol. 2016;263:2555–64.
doi: 10.1007/s00415-016-8212-2
pubmed: 27401178
Podnar S, Vodušek DB. Lower urinary tract dysfunction in patients with peripheral nervous system lesions. Handb Clin Neurol. 2015;130:203–24.
doi: 10.1016/B978-0-444-63247-0.00012-2
pubmed: 26003246
New frontiers of basic science research in. neurogenic lower urinary tract dysfunction - PubMed. https://pubmed.ncbi.nlm.nih.gov/28716328/ . Accessed 13 Apr 2024.
Smith PP, DeAngelis A, Kuchel GA. Detrusor expulsive strength is preserved, but responsiveness to bladder filling and urinary sensitivity is diminished in the aging mouse. Am J Physiol Regul Integr Comp Physiol. 2012;302:R577–586.
doi: 10.1152/ajpregu.00508.2011
pubmed: 22204955
Barboglio Romo PG, Gupta P. Peripheral and sacral neuromodulation in the treatment of neurogenic lower urinary tract dysfunction. Urol Clin N Am. 2017;44:453–61.
doi: 10.1016/j.ucl.2017.04.011
Tanagho EA, Schmidt RA. Bladder pacemaker: scientific basis and clinical future. Urology. 1982;20:614–9.
doi: 10.1016/0090-4295(82)90312-0
pubmed: 7179629
Hanno PM, Erickson D, Moldwin R, Faraday MM, American Urological Association. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193:1545–53.
doi: 10.1016/j.juro.2015.01.086
pubmed: 25623737
Moore CK, Rueb JJ, Derisavifard S. What is new in neuromodulation? Curr Urol Rep. 2019;20:55.
doi: 10.1007/s11934-019-0920-6
pubmed: 31388779
Wiener JS, Chaudhry R. Neurogenic lower urinary tract dysfunction. Urol Clin N Am. 2023;50:415–32.
doi: 10.1016/j.ucl.2023.04.002
Chen G, Liao L, Deng H. The effect of sacral neuromodulation in ambulatory spina bifida patients with neurogenic bladder and bowel dysfunction. Urology. 2021;153:345–50.
doi: 10.1016/j.urology.2020.11.075
pubmed: 33556449